Lv4
470 积分 2021-10-19 加入
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
21天前
已完结
No impact of low-dose nivolumab addition to JNJ-73763989 on HBsAg declines in chronic hepatitis B: the OCTOPUS-1 study
21天前
已完结
Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study
21天前
已完结
Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment
21天前
已完结
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
21天前
已完结
LBP-008 Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507
2个月前
已完结
EASL Congress 2025
2个月前
已完结
The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729–001): a phase 1a/b trial
2个月前
已完结
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics
2个月前
已完结
Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
3个月前
已完结
皖公网安备34019202002308
